Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prexasertib - Acrivon Therapeutics/SOM Biotech

Next Previous
Drug Profile

Prexasertib - Acrivon Therapeutics/SOM Biotech

Alternative Names: ACR 368; Captisol® enabled prexasertib; LY 2606368 MsOH H2O; LY-2606368; Prexasertib Mesylate Monohydrate - Acrivon Therapeutics/ SOM Biotech

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma; Eli Lilly and Company
  • Developer Acrivon Therapeutics; Children's Oncology Group; Dana-Farber Cancer Institute; Eli Lilly and Company; Ewha Womans University; National Cancer Institute (USA); SOM Biotech
  • Class Antineoplastics; Antivirals; Nitriles; Pyrazines; Pyrazoles; Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors; Coronavirus 3C-like proteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anal cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Endometrial cancer; Solid tumours; Squamous cell cancer
  • Phase I/II Urogenital cancer
  • No development reported Brain cancer; COVID 2019 infections
  • Discontinued Acute myeloid leukaemia; Bladder cancer; Colorectal cancer; Fallopian tube cancer; Head and neck cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Triple negative breast cancer

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Combination therapy) in USA
  • 22 Jul 2025 Discontinued - Phase-I/II for Ovarian cancer (Inoperable/Unresectable, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 22 Jul 2025 Discontinued - Phase-I/II for Ovarian cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease, Monotherapy, Inoperable/Unresectable) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top